SCHEMBL6920104

SCHEMBL6920104

CN(C)C(c1ccccc1)C(N)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.56
AOC3 Q16853 5/20 0.48
F2 P00734 1/20 0.44
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 1/20 0.42
SLC6A2 P23975 2/20 0.42
SLC6A4 P31645 2/20 0.42
HTR2A P28223 1/20 0.41
HRH1 P35367 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
SLC6A3 Q01959 1/20 0.41
KCNH2 Q12809 1/20 0.41
ADRA2A P08913 1/20 0.40
ADRA2C P18825 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
LMNA P02545 1/20 0.40
HIF1A Q16665 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6920106 1.00 DPP4 (0.56) DPP4AOC3F2KDM4EALDH1A1
SCHEMBL6920099 1.00 DPP4 (0.56) DPP4AOC3F2KDM4EALDH1A1
SCHEMBL5173218 0.85 DPP4 (0.50) DPP4AOC3F2KDM4EALDH1A1
SCHEMBL7586902 0.83 HTR2A (0.52) AOC3KDM4EALDH1A1SLC6A2SLC6A4
SCHEMBL17571131 0.82 AOC3 (0.53) DPP4AOC3F2KDM4EALDH1A1
SCHEMBL19614378 0.82 AOC3 (0.53) DPP4AOC3F2KDM4EALDH1A1
SCHEMBL28826602 0.78 CYP3A4 (0.39) DPP4ALDH1A1SLC6A2SLC6A4CYP3A4
SCHEMBL26308183 0.78 DPP4 (0.46) DPP4AOC3F2KDM4ESLC6A2
SCHEMBL14350621 0.77 KDM4E (0.57) DPP4AOC3F2KDM4EALDH1A1
SCHEMBL29061569 0.77 DPP4 (0.50) DPP4AOC3F2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112105680-A Solid dispersion, method for preparing the same, chain-extended polyurethane using the same, and epoxy resin composition comprising the same 株式会社三养社 2020-12-18 CN claimed
CN-120554243-A Synthesis method of beta adamantyl amide compound 南京工业大学 2025-08-29 CN disclosed
US-20250051434-A1 MONOVALENT INTERLEUKIN 12 (IL-12) HETERODIMERIC FC PROTEINS MERCK SHARP & DOHME LLC (US) 2025-02-13 US disclosed
CN-118420500-A Chiral organic catalyst and preparation method and application thereof 苏州源锂新材料科技有限公司 2024-08-02 CN disclosed
CN-112105680-A Solid dispersion, method for preparing the same, chain-extended polyurethane using the same, and epoxy resin composition comprising the same 株式会社三养社 2020-12-18 CN disclosed
WO-2019216700-A1 SOLID DISPERSION, PREPARATION METHOD THEREFOR, CHAIN-EXTENDED POLYURETHANE USING SAME, AND EPOXY RESIN COMPOSITION COMPRISING SAME 주식회사 삼양사 (KR) 2019-11-14 WO disclosed
EP-2694466-B1 PREPARATION OF SITAGLIPTIN INTERMEDIATES LEK PHARMACEUTICALS (SI) 2018-10-24 EP disclosed
CN-105802196-B A kind of high molecular material and preparation method thereof with double process shape-memory effect 中山大学 2018-08-07 CN disclosed
US-9174930-B2 Preparation of sitagliptin intermediates LEK PHARMACEUTICALS D.D. (SI) 2015-11-03 US disclosed
US-20140213810-A1 PREPARATION OF SITAGLIPTIN INTERMEDIATES LEK PHARMACEUTICALS D.D. (SI) 2014-07-31 US disclosed
EP-2623509-A1 Method of producing an optically active amine compound by catalytic asymmetric hydrogenation using a ruthenium-diphosphine complex Kanto Kagaku Kabushiki Kaisha (JP) 2013-08-07 EP disclosed
US-20130197234-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2013-08-01 US disclosed
CN-101225065-B Chiral compound having multi-hydrogen bonds dual-function as well as synthetic method and use thereof UNIV WUHAN 2011-05-11 CN disclosed
CN-101225065-A Chiral compound having multi-hydrogen bonds dual-function as well as synthetic method and use thereof UNIV WUHAN (CN) 2008-07-23 CN disclosed
WO-2004031168-A2 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF OPTICALLY ACTIVE 3-AMINO-1-(2-THIENYL)-1-PROPANOL DERIVATIVES LONZA AG (CH) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051434-A1 MONOVALENT INTERLEUKIN 12 (IL-12) HETERODIMERIC FC PROTEINS IL2RA, IL2, FCGR2A DPP4 4806/4885AOC3 4731/4885F2 905/4885
US-20130197234-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND HRH3, TDO2, SRM DPP4 3863/4885AOC3 523/4885F2 2592/4885
US-20140213810-A1 PREPARATION OF SITAGLIPTIN INTERMEDIATES DPP4, DPP3, DPP9 DPP4 1/4885AOC3 4321/4885F2 2536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.